Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Bulletin Haiti.
Press releases published on July 31, 2025
PL BioScience Announces Major Site Expansion
GlobeNewswire
·
July 31, 2025
New 1,200 m² facility in Aachen expands headquarters to support company growth and scale Human Platelet Lysate production Site provides the world’s largest HPL output with 20,000L annual capacity and a dual-source GMP strategy for secure, resilient supply …
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
GlobeNewswire
·
July 31, 2025
(OXFORDSHIRE, England …
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
GlobeNewswire
·
July 31, 2025
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59 Pharma launches increased sales by 39.8%, …
Communiqué de presse : T2 : croissance à deux chiffres desventes, nette progression du BNPA des activités ; perspectives de ventes 2025 revues à la hausse avec une croissance désormais attendue dans le haut de la fourchette à un chiffre
GlobeNewswire
·
July 31, 2025
T2 : croissance à deux chiffres des ventes, nette progression du BNPA des activités ; perspectives de ventes 2025 revues à la hausse avec une croissance désormais attendue dans le haut de la fourchette à un chiffre Paris, le 31 juillet 2025 Ventes du T2 en …
Pharming Group reports second quarter and first half 2025 financial results and provides business update
GlobeNewswire
·
July 31, 2025
Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growth RUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second …
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
GlobeNewswire
·
July 31, 2025
$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional …
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
GlobeNewswire
·
July 31, 2025
H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in Rare Disease, 9.7% in Neuroscience, and 6.4% in Oncology H1 core operating income of €656m, growing by 21.9% as reported, with a core operating …
Ipsen publie de solides résultats au premier semestre 2025 et relève ses objectifs financiers annuels
GlobeNewswire
·
July 31, 2025
Croissance des ventes totales du Groupe de 11,4% à taux de change constant1 ou 9,7% en données publiées, tirée par les trois aires thérapeutiques : 95,7% dans les Maladies Rares, 9,7% en Neurosciences et 6,4% en Oncologie Résultat opérationnel des …
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
GlobeNewswire
·
July 31, 2025
BENGALURU, India, July 31, 2025 (GLOBE NEWSWIRE) -- VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform cutting drug discovery timelines in half alongside a strategic …
Prime Medicine Announces Pricing of Public Offering
GlobeNewswire
·
July 31, 2025
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten …
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
GlobeNewswire
·
July 31, 2025
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, …